Local 12, WCPO highlight brain tumor vaccine trial
Local television stations Local 12 and WCPO recently highlighted the Imvax trial that will test a personalized immunotherapy approach designed to work similarly to a vaccine by training the immune system to fight glioblastomas, a deadly brain tumor.
The University of Cincinnati is a study site for the new Phase 2b clinical trial, and Soma Sengupta, MD, PhD, is the site principal investigator.
In the trial, glioblastoma patients will have their tumors removed, and then their tumor cells will be combined with a novel drug to create a personalized vaccine. The combination is then inserted into the patients' abdomens, allowing the immune system to train to fight the tumor cells.
"The patient is making their own antibodies, and their own immune system is working to try and beat this cancer," Sengupta told Local 12.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
Improving treatment for deadly brain tumors
May 5, 2023
The University of Cincinnati's Soma Sengupta was a co-first author on research published in Cell Reports Medicine New that found that a cancer stem cell test can accurately decide more effective treatments and lead to increased survival for patients with glioblastoma, a deadly brain tumor.
Personalized immunotherapy to fight deadly brain tumors
April 13, 2023
The University of Cincinnati is enrolling patients in an Imvax study that will test the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
Local 12, WCPO highlight brain tumor vaccine trial
April 21, 2023
Local 12 and WCPO highlighted the Imvax trial being hosted at the University of Cincinnati that is testing the effectiveness of a personalized vaccine approach to fight deadly brain tumors.
Learning more about how cancer affects stroke risk
October 16, 2023
A collaborative team led by University of Cincinnati, University of North Carolina and Duke University researchers is studying how specific cancers and treatments affect patients' risk of stroke.
Collaborative University of Cincinnati Cancer Center team opens Phase 2 brain tumor trial
March 26, 2024
A multidisciplinary team of University of Cincinnati Cancer Center researchers have opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, the most deadly form of brain tumors.
WVXU: Does your spinal fluid show if you have a tumor?
November 9, 2020
University of Cincinnati researchers are starting a clinical trial to determine if they can detect brain cancer in spinal fluid.
UC researchers study ‘liquid biopsy’
October 15, 2020
Researchers at the University of Cincinnati are investigating a new way to explore suspicious brain masses, potentially eliminating the need for unnecessary surgery and worry for patients.
Using data to improve care for traumatic brain injuries
November 16, 2023
The University of Cincinnati Gardner Neuroscience Institute's Brandon Foreman recently published survey results identifying areas of consensus and needs for further research to develop a standard practice for comprehensively monitoring brain health in the intensive care unit.
UC Gardner Neuroscience Institute launches clinical trial for personalized pain management
November 13, 2023
A new clinical trial underway at the UC Gardner Neuroscience Institute is applying a personalized approach to pain management that doctors hope can improve post-surgical pain, reduce opioid dependence and reduce length of hospital stays.
Memphis, Tennessee news: UC researchers pioneering research to treat 'brain tsunamis'
May 9, 2024
Memphis, Tennessee television station Action News 5 featured research from the University of Cincinnati's Laura Ngwenya and Jed Hartings that is testing the first treatments for spreading depolarizations, abnormal brain activity also called a "brain tsunami."